Venturepharm Group has established a collaboration with Canadian biotech Lorus Therapeutics to develop Lorus’ portfolio of cancer drugs. Lorus has eight molecules in its pipeline. Venturepharm also announced that it has absorbed Acesys Pharmatech, a Nanjing global drug discovery CRO with about 70 chemists, into its China-located Exelgen operation. More details...

Stock Symbols: (AMEX: LRP) (HKSE: 8225) (NSDQ: CBTE)